EDBI Logo
|  
Flyout Menu

Erasca IPOs on Nasdaq

Erasca IPOs on Nasdaq

EDBI has been part of Erasca’s journey since our investment in 2020, and celebrates with the team as their IPO bolsters the company’s war chest and accelerates development of their comprehensive suite of drugs targeting the Ras/MAPK pathway, furthering their mission of erasing cancer.

 

Read Erasca’s press release here:

https://investors.erasca.com/news-releases/news-release-details/erasca-announces-closing-initial-public-offering-and-full

 

Related Posts

Can Southeast Asia claim its place in the AI economy?

  • 04 06 2026
  • |
Read More

AlphaSense nearly doubles valuation to $7.5 billion in new funding round

  • 03 06 2026
  • |
Read More

Startup funding reaches $214m in April to May period

  • 03 06 2026
  • |
Read More

Alternative investing’s next phase: tackling portfolio challenges

  • 26 05 2026
  • |
Read More

Notice: Unauthorised use of the EDBI name and branding

  • 26 05 2026
  • |
Read More

Exaforce raises $125M Series B to expand AI-native security operations platform

  • 13 05 2026
  • |
Read More

Join our community!

Subscribe to our quarterly e-Newsletter, The Upside to find out what’s shaping the future industries of Singapore and the region.

Subscribe now

Investing in high-growth technologies that shape the future economic pillars of Singapore since 1991.

About EDBI

Team

Portfolio

News and Insights

Careers

Contact Us

Linkedin Youtube

© 2025 EDBI. All rights reserved.

Notice: Unauthorised use of the EDBI name and branding in Japan. EDBI officers will never solicit from the public or offer incentives for participation in our programmes. Report any incident to [email protected] if you are unsure if something is a scam.
Learn more
This is default text for notification bar
Learn more